Evidence map›Paper›PMID 32517691›Full record

ArticleBMC veterinary research2020

Duration of immunity against heterologous porcine parvovirus 1 challenge in gilts immunized with a novel subunit vaccine based on the viral protein 2.

Beatriz Garcia-Morante, Marta Noguera, Sonja Klocke, Kathrin Sommer, Philip Bridger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Beatriz Garcia-MoranteCentcinc, C/Montserrat de Casanovas 105, 08032, Barcelona, Spain. bea.garciamorante@gmail.com.ORCID http://orcid.org/0000-0002-5610-9932
Marta NogueraBoehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Bemeroder Straβe 31, 30559, Hannover, Germany.
Sonja KlockeBoehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Bemeroder Straβe 31, 30559, Hannover, Germany.
Kathrin SommerBoehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Bemeroder Straβe 31, 30559, Hannover, Germany.
Philip BridgerBoehringer Ingelheim Vetmedica GmbH, Binger Straβe 173, 55216, Ingelheim, Germany.
Boehringer Ingelheim (Germany) · DEConsorci Sanitari Garraf · ES

Funding

Boehringer Ingelheim Animal Health, Inc. Not applicable
6 · The paper itself

Abstract

backgroundPorcine parvovirus 1 (PPV1) is widespread in commercial pig farms worldwide and has a significant impact to the swine industry. Long-lasting immunity achieved by means of vaccination is the main tool to prevent PPV1 infection and its associated clinical signs. Here we evaluated the duration of immunity (DOI) conferred by a novel subunit vaccine based on the viral protein (VP) 2 of PPV1, named ReproCyc® ParvoFLEX. The DOI was assessed at 6 months post-vaccination following the standard vaccination scheme (phase I) or after re-vaccination (phase II) with a single injection administered 24 weeks after the basic vaccination scheme. A total of 46, five to six-month-old gilts, free of PPV1 and porcine reproductive and respiratory syndrome virus (PRRSV), were randomly assigned to 6 groups (three in each phase): the negative control groups were inoculated with sodium chloride (NaCl), the vaccinated groups were immunized with the PPV1 subunit vaccine and the strict controls were neither treated nor challenged. Subsequently, the negative control and vaccinated groups from each phase were challenged with a heterologous PPV1 strain. Infection of fetuses was the primary outcome parameter for efficacy, though other supportive parameters were PPV1 viremia and serological status of the gilts and the condition of their fetuses (i.e. normal, autolytic, or mummified).

resultsAll gilts vaccinated against PPV1 tested seropositive at challenge and viremia after challenge was detectable only in the non-vaccinated animals. In this regard, fetuses positive to PPV1 by PCR were only found in litters from non-vaccinated sows.

conclusionsThese results point out that the immunity developed by the PPV1 subunit vaccine is effective in terms of preventing viremia, transplacental infection of fetuses and fetal death caused by PPV1 infection. ReproCyc® ParvoFLEX was demonstrated to protect fetuses against heterologous PPV1 challenge with a DOI of 6 months after vaccination.

Indexed as

AnimalsFemaleFetusImmunizationParvoviridae InfectionsParvovirus, PorcinePregnancyPregnancy Complications, InfectiousSus scrofaSwineSwine DiseasesVaccinationVaccines, SubunitViral ProteinsViral VaccinesVaccines, SubunitViral ProteinsViral VaccinesDuration of immunityMass vaccinationPigsPorcine parvovirusSubunit vaccineVaccine efficacy

Identifiers

PMID32517691
PMCPMC7285602
OpenAlexW3033795309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.